Results 1 to 10 of about 112,154 (311)

Bacterial vaccines in poultry [PDF]

open access: yesBulletin of the National Research Centre, 2020
Background Poultry bacterial pathogens are mainly controlled by using high-cost sanitary measures and medical treatment. However, the drug-resistant strains of pathogens continuously emerge, and medical treatments are often ineffective.
Nagwa S. Rabie, Zeinab M. S. Amin Girh
doaj   +6 more sources

Bacterial vaccines and antibiotic resistance. [PDF]

open access: diamondUps J Med Sci, 2014
Spread of antibiotic resistance is mediated by clonal lineages of bacteria that besides being resistant also possess other properties promoting their success. Some vaccines already in use, such as the pneumococcal conjugate vaccines, have had an effect on these successful clones, but at the same time have allowed for the expansion and resistance ...
Henriques-Normark B, Normark S.
europepmc   +6 more sources

A Comprehensive Review on Bacterial Vaccines Combating Antimicrobial Resistance in Poultry [PDF]

open access: yesVaccines, 2023
Bacterial vaccines have become a crucial tool in combating antimicrobial resistance (AMR) in poultry. The overuse and misuse of antibiotics in poultry farming have led to the development of AMR, which is a growing public health concern.
Md. Saiful Islam, Md. Tanvir Rahman
doaj   +2 more sources

Bacterial Spores as Vaccine Vehicles [PDF]

open access: greenInfection and Immunity, 2003
ABSTRACT For the first time, bacterial spores have been evaluated as vaccine vehicles. Bacillus subtilis spores displaying the tetanus toxin fragment C (TTFC) antigen were used for oral and intranasal immunization and were shown to generate mucosal and systemic responses in a murine model.
Le H. Duc   +4 more
openalex   +4 more sources

Determination of Endotoxicity in Bacterial Vaccines [PDF]

open access: goldApplied Microbiology, 1973
Endotoxicity of bacterial vaccines was quantitated in mice by using actinomycin D as potentiating agent. The results were compared with those obtained by the mouse weight gain test. The lethality of Escherichia coli lipopolysaccharide was increased 2,140 times when 12.5 μg of actinomycin D was used.
K. H. Wong   +3 more
openalex   +4 more sources

Immunological Insights and Therapeutic Advances in COPD: Exploring Oral Bacterial Vaccines for Immune Modulation and Clinical Improvement [PDF]

open access: yesVaccines
Chronic obstructive pulmonary disease (COPD) is a prevalent chronic condition associated with substantial global morbidity and mortality. Primarily caused by prolonged exposure to harmful agents such as dust and gases, COPD is characterized by persistent
Sławomir Lewicki   +8 more
doaj   +2 more sources

Bacterial pathogen genomics and vaccines [PDF]

open access: bronzeBritish Medical Bulletin, 2002
Infectious diseases remain a major cause of deaths and disabilities in the world, the majority of which are caused by bacteria. Although immunisation is the most cost effective and efficient means to control microbial diseases, vaccines are not yet available to prevent many major bacterial infections.
Richard Moxon, Rino Rappuoli
openalex   +4 more sources

Bacterial Proteomics and Vaccine Development [PDF]

open access: bronzeAmerican Journal of PharmacoGenomics, 2002
Until recently, the development of vaccines for use in humans relied on the response to attenuated or whole-cell preparations, or empirically selected antigens. The post-genomic era holds the possibility of rational design of novel vaccines for important human pathogens.
Carol L. Nilsson
openalex   +4 more sources

Epitope-Based Vaccines: The Next Generation of Promising Vaccines Against Bacterial Infection [PDF]

open access: yesVaccines
The increasing resistance of bacteria to antibiotics has underscored the need for new drugs or vaccines to prevent bacterial infections. Reducing multidrug resistance is a key objective of the WHO’s One Health initiative.
Jing Li   +4 more
doaj   +2 more sources

Clinical trial of tolerability, safety, and immunogenicity of the Russian influenza inactivated split vaccine Flu-m in children from 6 months to 9 years of age

open access: yesЖурнал инфектологии, 2023
Purpose: To study the reactogenicity, safety and immunogenicity of the Russian vaccine Flu-M in comparison with Vaxigrip vaccine for influenza prevention in children aged from 6 months to 9 years (phase III).Materials and Methods.
A. M. Korolyuk   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy